Impact of multi-cohort HPV vaccination on cervical cancer in women below 30 years of age: Lessons learned from the Scandinavian countries.

In Scandinavia, HPV vaccination programs started in 2007/8; in Sweden and Denmark with HPV vaccination offered to multiple cohorts of young girls, while in Norway offered to a single cohort only. Interestingly, in Sweden and Denmark, cervical cancer incidence in young women decreased markedly from 2017/2018, while in Norway a steady increase was seen until 2020. As the three countries are very similar in other factors important for cervical cancer incidence rates like cervical cancer screening, the observed difference is most likely due to differences in the multi-cohort vaccination.

Long-term effectiveness of the nine-valent human papillomavirus vaccine: Interim results after 12 years of follow-up in Scandinavian women.

A pivotal study in women aged 16-26 years demonstrated that the nine-valent human papillomavirus (9vHPV) vaccine was efficacious against high-grade cervical dysplasia related to the HPV types covered by the vaccine. To evaluate whether effectiveness remains above 90% for up to 14 years post-vaccination, a long-term follow-up (LTFU) extension of the study was conducted in Denmark, Norway, and Sweden ( = 2,029). Interim findings at 12 years post-vaccination are reported.